Connect your AI

Nuvation Bio NUVB Deferred income

Deferred income at other companies

MPLXMPLX

$115M-63.7%

Arteris, Inc.AIP

$6.16M-16.1%

Arthur J. GallagherAJG

$177M+167%

Williams CompaniesWMB

$170M+6.9%

UnitedHealth GroupUNH

$3.42B+3.7%

Lantheus HoldingsLNTH

$6.6M—

Other financials

Income statement

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation

Market cap$2.25B+150%

Profitability

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Nuvation Bio's deferred income?: Nuvation Bio (NUVB) reported deferred income of $151.89M in Q1 2026.